These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Experimental treatment may show promise for vCJD. Pincock S Lancet; 2003 Oct; 362(9390):1130. PubMed ID: 14558510 [No Abstract] [Full Text] [Related]
7. Experimental treatments for human transmissible spongiform encephalopathies: is there a role for pentosan polysulfate? Rainov NG; Tsuboi Y; Krolak-Salmon P; Vighetto A; Doh-Ura K Expert Opin Biol Ther; 2007 May; 7(5):713-26. PubMed ID: 17477808 [TBL] [Abstract][Full Text] [Related]
8. Family finds hospital willing to give experimental CJD treatment. Dyer O BMJ; 2003 Jan; 326(7379):8. PubMed ID: 12511437 [No Abstract] [Full Text] [Related]
9. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Bone I; Belton L; Walker AS; Darbyshire J Eur J Neurol; 2008 May; 15(5):458-64. PubMed ID: 18355301 [TBL] [Abstract][Full Text] [Related]
10. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion. Honda H; Sasaki K; Minaki H; Masui K; Suzuki SO; Doh-Ura K; Iwaki T Neuropathology; 2012 Apr; 32(2):124-32. PubMed ID: 21801238 [TBL] [Abstract][Full Text] [Related]
11. [New knowledge about Creutzfeldt-Jakob disease can yield therapeutic possibilities]. Stølsmark T; Tysnes OB Tidsskr Nor Laegeforen; 2010 Mar; 130(6):601-4. PubMed ID: 20349004 [TBL] [Abstract][Full Text] [Related]
12. Second vCJD patient to receive experimental treatment. Dyer C BMJ; 2003 Oct; 327(7420):886. PubMed ID: 14563724 [No Abstract] [Full Text] [Related]
13. Medicines committee felt unable to recommend use of pentosan polyphosphate in vCJD. Gould M BMJ; 2003 Oct; 327(7418):770. PubMed ID: 14525869 [No Abstract] [Full Text] [Related]
14. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Farquhar C; Dickinson A; Bruce M Lancet; 1999 Jan; 353(9147):117. PubMed ID: 10023899 [No Abstract] [Full Text] [Related]
15. Small improvement seen in teenager with vCJD. Mayor S BMJ; 2003 Oct; 327(7418):765. PubMed ID: 14525852 [No Abstract] [Full Text] [Related]
16. Systemic use of pentosan polysulphate in the treatment of osteoarthritis. Read RA; Cullis-Hill D; Jones MP J Small Anim Pract; 1996 Mar; 37(3):108-14. PubMed ID: 8683953 [TBL] [Abstract][Full Text] [Related]
17. Creutzfeldt-Jakob disease: hopes for therapy. Pocchiari M; Ladogana A; Graziano S; Puopolo M Eur J Neurol; 2008 May; 15(5):435-6. PubMed ID: 18394045 [No Abstract] [Full Text] [Related]
18. Improved clinical outcome measures of knee pain and function with concurrent resolution of subchondral Bone Marrow Edema Lesion and joint effusion in an osteoarthritic patient following Pentosan Polysulphate Sodium treatment: a case report. Sampson MJ; Kabbani M; Krishnan R; Nganga M; Theodoulou A; Krishnan J BMC Musculoskelet Disord; 2017 Sep; 18(1):396. PubMed ID: 28899386 [TBL] [Abstract][Full Text] [Related]
19. Continuous intraventricular infusion of pentosan polysulfate: clinical trial against prion diseases. Tsuboi Y; Doh-Ura K; Yamada T Neuropathology; 2009 Oct; 29(5):632-6. PubMed ID: 19788637 [TBL] [Abstract][Full Text] [Related]
20. The effect of three different doses of sodium pentosan polysulphate on haematological and haemostatic variables in adult horses. Dart A; Perkins N; Dowling ; Batterham T; Livingston C; Hodgson D Aust Vet J; 2001 Sep; 79(9):624-7. PubMed ID: 11702935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]